skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer

Cancer imaging, 2019-06, Vol.19 (1), p.37-37, Article 37 [Peer Reviewed Journal]

COPYRIGHT 2019 BioMed Central Ltd. ;COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1470-7330 ;ISSN: 1740-5025 ;EISSN: 1470-7330 ;DOI: 10.1186/s40644-019-0220-x ;PMID: 31186052

Full text available

Citations Cited by
  • Title:
    68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
  • Author: Damjanovic, Jonathan ; Janssen, Jan-Carlo ; Prasad, Vikas ; Diederichs, Gerd ; Walter, Thula ; Brenner, Winfried ; Makowski, Marcus R
  • Subjects: Amputation ; Androgens ; Antigens ; Cancer metastasis ; Cancer patients ; CAT scans ; Computed tomography ; CT imaging ; Diagnosis ; Diagnostic imaging ; Emission analysis ; Liver ; Liver cancer ; Liver metastasis ; Medical imaging ; Metastasis ; Parameter identification ; Patient outcomes ; Patients ; PET imaging ; PET/CT ; Positron emission ; Positron emission tomography ; Prostate cancer ; PSMA ; Studies ; Tomography
  • Is Part Of: Cancer imaging, 2019-06, Vol.19 (1), p.37-37, Article 37
  • Description: Background The purpose of this study was to evaluate the imaging properties of hepatic metastases in .sup.68Ga-PSMA positron emission tomography (PET) in patients with prostate cancer (PC). Methods .sup.68Ga-PSMA-PET/CT scans of PC patients available in our database were evaluated retrospectively for liver metastases. Metastases were identified using .sup.68Ga-PSMA-PET, CT, MRI and follow-up scans. Different parameters including, maximum standardized uptake values (SUV.sub.max) of the healthy liver and liver metastases were assessed by two- and three-dimensional regions of interest (2D/3D ROI). Results One hundred three liver metastases in 18 of 739 PC patients were identified. In total, 80 PSMA-positive (77.7%) and 23 PSMA-negative (22.3%) metastases were identified. The mean SUV.sub.max of PSMA-positive liver metastases was significantly higher than that of the normal liver tissue in both 2D and 3D ROI (p [less than or equai to] 0.05). The mean SUV.sub.max of PSMA-positive metastases was 9.84 [+ or -] 4.94 in 2D ROI and 10.27 [+ or -] 5.28 in 3D ROI; the mean SUV.sub.max of PSMA-negative metastases was 3.25 [+ or -] 1.81 in 2D ROI and 3.40 [+ or -] 1.78 in 3D ROI, and significantly lower than that of the normal liver tissue (p [less than or equai to] 0.05). A significant (p [less than or equai to] 0.05) correlation between SUV.sub.max in PSMA-positive liver metastases and both size ([rho].sub.Spearman = 0.57) of metastases and PSA serum level ([rho].sub.Spearman = 0.60) was found. Conclusions In .sup.68Ga-PSMA-PET, the majority of liver metastases highly overexpress PSMA and is therefore directly detectable. For the analysis of PET images, it has to be taken into account that also a significant portion of metastases can only be detected indirectly, as these metastases are PSMA-negative. Keywords: Liver metastasis, PSMA, PET/CT, Prostate cancer
  • Publisher: London: BioMed Central Ltd
  • Language: English
  • Identifier: ISSN: 1470-7330
    ISSN: 1740-5025
    EISSN: 1470-7330
    DOI: 10.1186/s40644-019-0220-x
    PMID: 31186052
  • Source: Geneva Foundation Free Medical Journals at publisher websites
    PubMed Central
    Springer OA刊
    ProQuest Central
    DOAJ Directory of Open Access Journals

Searching Remote Databases, Please Wait